A LARGE MULTIPLE ENDOCRINE NEOPLASIA TYPE-1 FAMILY WITH CLINICAL EXPRESSION SUGGESTIVE OF ANTICIPATION

Citation
S. Giraud et al., A LARGE MULTIPLE ENDOCRINE NEOPLASIA TYPE-1 FAMILY WITH CLINICAL EXPRESSION SUGGESTIVE OF ANTICIPATION, The Journal of clinical endocrinology and metabolism, 82(10), 1997, pp. 3487-3492
Citations number
25
Categorie Soggetti
Endocrynology & Metabolism
ISSN journal
0021972X
Volume
82
Issue
10
Year of publication
1997
Pages
3487 - 3492
Database
ISI
SICI code
0021-972X(1997)82:10<3487:ALMENT>2.0.ZU;2-G
Abstract
We describe a large multigenerational multiple endocrine neoplasia Typ e 1 (MEN1) family with clinical expression suggestive of anticipation. In the second and third generations, two deceased obligate gene carri ers died at the ages of 85 and 76 without the history of MEN1, whereas two other living gene carriers above the age of 65 have had no clinic al evidence of MEN1 to date. In the fourth generation, eight members w ere affected, with four having severe MEN1-related and atypical malign ancies: a case of metastatic endocrine pancreatic tumor, two cases of metastatic thymic carcinoids, and a case of spinal ependymoma. In the fifth generation, all five patients were below the age of 22 when the disease was detected. MEN1 was confirmed in the family by linkage anal ysis using MEN1-linked microsatellite markers and by identification of a nonsense mutation in the MEN1/menin gene. Alleotyping showed loss o f heterozygosity (LOH) involving the wild-type alleles in seven tumors in the family including the ependymoma, which is the first MEN1-relat ed case that shows genetic abnormality in chromosome 11q13, suggesting that MEN1 gene might be involved in the tumorigenesis of a subset of ependymomas. In relation to clinical anticipation, repeated expansion studies were carried out but failed to detect any expansion. We conclu de that this is a unique MEN1 family and that an unknown genetic mecha nism might be contributing to the anticipation phenomenon. We demonstr ate in this family that all gene carriers, including the very young me mbers, will need close and careful follow-up.